Colgate-Palmolive's Price Target Lowered to $106 by UBS
ByAinvest
Thursday, Jul 17, 2025 11:30 pm ET1min read
BCS--
Colgate-Palmolive has been the subject of various research reports in recent months. Barclays lifted its target price on the stock from $86 to $87, giving it an "equal weight" rating. Wells Fargo & Company increased its target price from $83 to $88, but assigned an "underweight" rating. JPMorgan Chase & Co. boosted its price target from $95 to $103, giving the stock an "overweight" rating. Citigroup raised its target price from $103 to $108, maintaining a "buy" rating. Piper Sandler reduced its target price from $108 to $107, assigning an "overweight" rating [1].
Colgate-Palmolive's stock has seen mixed reactions from analysts. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $101.00. Institutional investors own 80.41% of the company's stock [1].
Institutional investors have shown interest in Colgate-Palmolive. Westend Capital Management LLC increased its stake in the company by 111.1% during the first quarter. Cornerstone Planning Group LLC raised its holdings by 1,913.3%. Saudi Central Bank, Vermillion Wealth Management Inc., and Bernard Wealth Management Corp. also purchased new stakes in the company [1].
Colgate-Palmolive announced a share repurchase plan on March 20, authorizing the company to repurchase up to $5.00 billion in shares. This move suggests that management believes the stock is undervalued [1].
Colgate-Palmolive operates through two segments: Oral, Personal, and Home Care, and Pet Nutrition. The company reported $0.91 earnings per share for the quarter ending April 25, beating analyst expectations by $0.05. The company's revenue for the quarter was $4.91 billion, down 3.0% year-over-year [1].
References:
[1] https://www.marketbeat.com/instant-alerts/ubs-group-has-lowered-expectations-for-colgate-palmolive-nysecl-stock-price-2025-07-17/
C--
CL--
JPM--
PIPR--
UBS lowered its price target on Colgate-Palmolive (CL) to $106 from $109 while maintaining a Buy rating. The move reflects the firm's confidence in the company's performance and growth prospects.
UBS Group has lowered its price target for Colgate-Palmolive (NYSE:CL) to $106 from $109 while maintaining a "Buy" rating on the stock. The move reflects UBS's confidence in Colgate-Palmolive's performance and growth prospects. The new target price suggests a potential upside of 21.45% from the company's previous close [1].Colgate-Palmolive has been the subject of various research reports in recent months. Barclays lifted its target price on the stock from $86 to $87, giving it an "equal weight" rating. Wells Fargo & Company increased its target price from $83 to $88, but assigned an "underweight" rating. JPMorgan Chase & Co. boosted its price target from $95 to $103, giving the stock an "overweight" rating. Citigroup raised its target price from $103 to $108, maintaining a "buy" rating. Piper Sandler reduced its target price from $108 to $107, assigning an "overweight" rating [1].
Colgate-Palmolive's stock has seen mixed reactions from analysts. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $101.00. Institutional investors own 80.41% of the company's stock [1].
Institutional investors have shown interest in Colgate-Palmolive. Westend Capital Management LLC increased its stake in the company by 111.1% during the first quarter. Cornerstone Planning Group LLC raised its holdings by 1,913.3%. Saudi Central Bank, Vermillion Wealth Management Inc., and Bernard Wealth Management Corp. also purchased new stakes in the company [1].
Colgate-Palmolive announced a share repurchase plan on March 20, authorizing the company to repurchase up to $5.00 billion in shares. This move suggests that management believes the stock is undervalued [1].
Colgate-Palmolive operates through two segments: Oral, Personal, and Home Care, and Pet Nutrition. The company reported $0.91 earnings per share for the quarter ending April 25, beating analyst expectations by $0.05. The company's revenue for the quarter was $4.91 billion, down 3.0% year-over-year [1].
References:
[1] https://www.marketbeat.com/instant-alerts/ubs-group-has-lowered-expectations-for-colgate-palmolive-nysecl-stock-price-2025-07-17/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet